Getting Ready for the Bounce: Oramed Pharmaceuticals, Inc (ORMP) Stock
Canaccord Genuity lowered the price target for the Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) stock from “a Buy” to “a Hold”. The rating was released on January 12, 2023, according to finviz. The research report from Canaccord Genuity has initiated the stock to Buy, with a price target set at $27. In their research brief published December […]
